Zonagen Board Nominates Ms. Nola Masterson and Dr. David Poorvin to Join Company's Board as Prospective Members.THE WOODLANDS, Texas -- Zonagen, Inc. (Nasdaq:ZONA)(PCX (1) A bitmapped graphics file format that handles monochrome, 2-bit, 4-bit, 8-bit and 24-bit color and uses RLE to achieve compression ratios of approximately 1.1:1 to 1.5:1. Images with large blocks of solid colors compress best under the RLE method. See PC Paintbrush. :ZNG ZNG Zbor Nacionalne Garde (Croatian National Guard) ) today released that the Company's current Board of Directors ("Board") has nominated two additional members to join the Board pending approval by Zonagen shareholders at the Company's upcoming annual meeting to be held on September 29, 2004 in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of . The two nominees, Ms. Nola Masterson and Dr. David Poorvin, will stand for election at the upcoming meeting. Ms. Masterson holds an M.S. in Biological Science from George Washington University George Washington University, at Washington, D.C.; coeducational; chartered 1821 as Columbian College (one of the first nonsectarian colleges), opened 1822, became a university in 1873, renamed 1904. and advanced studies in related fields from the University of Florida University of Florida is the third-largest university in the United States, with 50,912 students (as of Fall 2006) and has the eighth-largest budget (nearly $1.9 billion per year). UF is home to 16 colleges and more than 150 research centers and institutes. . She was one of the first biotech analysts on Wall Street working with Drexel Burnham Lambert Drexel Burnham Lambert was a major Wall Street investment banking firm, which first rose to prominence and then was driven into bankruptcy in the 1980s by its involvement in illegal activities in the junk bond market, driven by Drexel employee Michael Milken. and Merrill Lynch. She was instrumental in the founding of the BioTech Meeting in Laguna Nigel, CA and the annual Biopharmaceutical Conference in Europe. Most recently she was a Venture Partner and remains a Senior Advisor to TVM TVM Time Value of Money (business, finance, economics) TVM Ticket Vending Machine TVM Thanks Very Much (logging abbreviation) TVM Transmission Voie Machine Techno Venture Management, as well as currently the Managing Member and General Partner of Science Futures LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , I, II, & III venture capital funds Venture Capital Funds An investment fund that manages money from investors seeking private equity stakes in small and medium-size enterprises with strong growth potential. Notes: . She is co-founder of Sequenom, Inc. a genetic analysis company located in San Diego and Hamburg, Germany. Nola has served as keynote speaker and moderator for several regional conferences that have focused on the unique challenges facing biotech companies in an evolving capital market. Dr. David Poorvin holds a Ph.D. from Rutgers University. He has over 30 years of experience in the pharmaceutical industry and is currently an Executive-in-Residence at Oxford Biosciences, a venture capital company. He is also engaged in private consulting for biotech companies. At the end of 2003, Dr. Poorvin retired from Schering-Plough Corporation as Vice President of their Business Development operations where he negotiated licenses, joint ventures and acquisitions of pharmaceutical products and research technologies. During and prior to his 22 years at Schering-Plough, Dr. Poorvin held positions in both preclinical and clinical development for Pfizer and Lederle Laboratories. He was responsible for several New Drug Applications ("NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ") programs including such drugs as Procardia and Imdur. Neither Ms. Masterson's nor Dr. Poorvin's present affiliations own stock in Zonagen. Joseph S. Podolski, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Zonagen, noted, "Speaking on behalf of our Board, I am pleased to present Ms. Masterson and Dr. Poorvin to our shareholders as prospective board members. Their addition will complement an already strong external board comprised of Jean Fourcroy M.D., Zsolt Lavotha and Dan Cain. --Dr. Fourcroy has extensive experience in the healthcare field including recently over 13 years of experience at the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. where she served as Medical Officer in the division responsible for reviewing Zonagen's current clinical development efforts. --Mr. Lavotha has more than 25 years of experience in the pharmaceutical industry where he held a variety of senior executive positions with Pfizer, Rhone-Poulenc Rohr, Lavipharm and Wyeth Ayerst, where he served as head of Wyeth's Europe/Africa/Middle East operations. --Mr. Cain has 35 years of broad business experience including 26 years with medical related companies of which 16 years were with biotechnology companies. Mr. Cain has held both chief executive positions as well as senior financial positions at several public and private companies. I am hopeful that our shareholders are as enthusiastic as I am in welcoming Nola and David to our Board." Mr. Podolski further stated, "I believe the addition of Ms. Masterson and Dr. Poorvin to our Board, along with the outside members already in place, creates a diversity of experience and capabilities critical to the success of developmental stage companies such as Zonagen. I am now confident that this Board has all the pieces necessary to weave the fabric of a strategic plan that will lead to both near term and long term improvement in shareholder value." ABOUT ZONAGEN Zonagen is engaged in the development of pharmaceutical products that address diseases and conditions associated with the human reproductive system The human reproductive system consists of:
Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to Zonagen's ability to have success in the clinical development of its technologies including Androxal(TM), uncertainty relating to Zonagen's patent portfolio and competing patents, Zonagen's ability to raise additional capital on acceptable terms or at all, Zonagen's ability to have success in meeting governmental regulations and the costs and time required to meet such regulatory requirements, and such other risks identified in Zonagen's Annual Report on Form 10-K for the year ended December 31, 2003, as filed with the Securities and Exchange Commission (SEC). These documents are available on request from Zonagen or at www.sec.gov. Zonagen disclaims any intention or obligation to update or revise any forward-looking statements |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion